-
Dr. Zhang Huilai: Groundbreaking Research in Hodgkin Lymphoma
01 CD47/PD-L1 Bispecific Antibody (IBI322) Treatment for PD-1 or PD-L1 Resistant Classical Hodgkin Lymphoma (cHL): Efficacy and Safety in Phase I Study Abstract Number: S216 Presenting Expert: Yu Jingwei, Tianjin…
-
Dr. Zhou Daobin: Exploring the Application of Sequential High-Dose Methotrexate in Newly Diagnosed Primary Central Nervous System Lymphoma Patients Without Chemotherapy
Background High-dose methotrexate (MTX) is widely used in frontline treatment for primary central nervous system lymphoma (PCNSL). Clinical data have shown that the new generation immunomodulator pomalidomide and Bruton kinase…
-
ABC7|Dr.Javier Cortes:Treatment directions and prospects for HER2+ advanced breast cancer treatment
HER2+ (HER2-positive) breast cancer is a type of breast cancer subtype with strong aggressiveness and poor prognosis. With the approval of more new targeted drugs for clinical application, the prognosis of HER2+ breast cancer patients continues to improve. In the absence of previous anti-HER2 targeted therapy, patients with HER2+ have a higher risk of recurrence.…
-
ABC7 | Dr.Ginny Mason:Working together to help breast cancer patients recover
The decisions faced by cancer patients are often many and complex. At present, the doctor-patient co-decision model is widely used in cancer patients. At the 7th International Consensus Conference on Advanced Breast Cancer (ABC7) “Patient advocacy session: Complexities of shared decision making “featured experts discussing complexities of shared decision making among patients.Oncology Frontier invited Dr.Ginny…
-
ABC7 | Dr.Eric P. Winer:Do a good job of managing advanced breast cancer patients
Since the 6th International Consensus Conference on Advanced Breast Cancer (ABC6), the field of advanced breast cancer treatment has changed a lot with the emergence of new therapeutic agents. At the 7th International Consensus Conference on Advanced Breast Cancer (ABC7), Oncology Frontier invited Dana-Farber Cancer Institute Dr.Eric P.Winer to share with us the changing treatment…
-
Dr.Hu Xichun &Hope S. Rugo: Future treatment strategies for advanced triple-negative breast cancer and HR+/ HER2-breast cancer from the perspective of ADC drug treatment progress
The International Consensus Conference on Advanced Breast Cancer (ABC) is the premier international conference in the academic field of advanced breast cancer, whose primary goal is to develop international consensus guidelines for the management of patients with advanced breast cancer. These guidelines are based on the latest evidence and can be used to guide treatment…
-
CDL (co-management of diabetes-liver diseases strategy,) Literature Monthly Review – November 2023, Issue 10
Introduction:Diabetes and liver diseases are common chronic conditions in China, and they interact in terms of pathogenesis, clinical manifestations, and therapeutic targets, often posing mutual risk factors. Co-management of these…
-
Impact of Treatment Adjustments on the Prognosis of “T+A” Therapy in Unresectable Hepatocellular Carcinoma
Editor’s Note: The combination of atezolizumab and bevacizumab (“T+A”) has emerged as the first-line standard treatment for unresectable hepatocellular carcinoma (uHCC) and is widely used in clinical practice. However, the…
Connecting Medical Expertise through Media